Psoriatic Arthritis: Joint and Cutaneous Inflammation
Psoriatic arthritis (PsA) is a chronic inflammatory disease that combines arthritis, enthesitis, dactylitis, and spondylitis with cutaneous manifestations of psoriasis — in a unified pathophysiological spectrum mediated by T cells, IL-17, and IL-23. It affects 20%–30% of patients with cutaneous psoriasis, with peak onset between 30 and 50 years and no sex predominance. It is a potentially erosive and disabling disease when not adequately treated.
PsA shares pathophysiological mechanisms with cutaneous psoriasis — particularly the IL-23/IL-17 pathway — which creates potential interest for complementary approaches that may act on both joint and cutaneous manifestations. Some biopsy studies have reported modulation of this pathway after acupuncture at BL-17 and SP-10 — preliminary findings that require confirmation.
Conventional Treatment of Psoriatic Arthritis
PsA treatment requires addressing both joint and cutaneous manifestations — with most biologics being effective in both domains.
THERAPEUTIC OPTIONS IN PSA
| DRUG | TARGET | EFFICACY (ACR20) | CUTANEOUS (PASI75) |
|---|---|---|---|
| NSAIDs | COX-1/2 | Symptomatic (pain/inflammation) | No cutaneous effect |
| Methotrexate | Antiproliferative (DMARD) | 41% ACR20 | PASI75 in 40% |
| Anti-TNF-α (adalimumab, etanercept) | TNF-α | 57%–58% ACR20 | PASI75 in 50%–65% |
| Anti-IL-17 (secukinumab, ixekizumab) | IL-17A | 54%–57% ACR20 | PASI75 in 70%–80% |
| Anti-IL-23 (guselkumab, risankizumab) | IL-23 | 56%–64% ACR20 | PASI75 in 75%–85% |
| Anti-IL-12/23 (ustekinumab) | IL-12 and IL-23 | 42% ACR20 | PASI75 in 60% |
Mechanisms of Action in Psoriatic Arthritis
Acupuncture acts on both domains of PsA — joint and cutaneous — through mechanisms that converge on the central inflammatory pathways of the disease.
Mechanisms of Action by Domain
1. Joint Domain — Analgesia and Reduction of Synovitis
LI-4 + LR-3 (Four Gates) activate the descending inhibitory pain pathways (PAG → raphe). Local periarticular points with EA at 2 Hz reduce synovitis through inhibition of prostaglandin release. DAS28 reduced by 0.9 points — clinically significant in PsA.
2. Cutaneous Domain — Hypothesis of IL-17/IL-23 Modulation via BL-17 and SP-10
BL-17 (Geshu) and SP-10 (Xuehai) are the points classically used in dermatological approaches in traditional reasoning. Some biopsy studies report reduction of IL-17 and IL-23 in psoriasis plaques after acupuncture at these points — preliminary findings suggesting an immunological modulation mechanism, although on a much smaller clinical scale than that of specific biologics.
3. Dactylitis — Needling of the "Sausage Digit"
Dactylitis is the most specific manifestation of PsA — involving digital synovitis + enthesitis + tenosynovitis. Peritendinous needling of the digital flexor sheath with EA at 2 Hz reduces edema and pain. The Ba Feng point (extra — between metatarsals on the dorsum of the foot) is especially effective for toe dactylitis.
4. Enthesitis — Peritendinous Needling
Achilles enthesitis: KI-3 + BL-60 with needling 2–3 mm from the insertion. Plantar fascia enthesitis: SP-1 + BL-61 perilesional. EA at 2 Hz on the affected tendon promotes controlled microscarring and local reduction of prostaglandins and pro-inflammatory cytokines.
For Arthritis and Pain
- • LI-4 + LR-3 — systemic analgesia
- • ST-36 + SP-6 — anti-inflammatory
- • LI-11 — heat/inflammation
- • Local points by affected joint
- • Ba Feng / Ba Xie for dactylitis
For Cutaneous Psoriasis
- • BL-17 — point of influence on the blood
- • SP-10 — "sea of blood", dermatoses
- • LU-7 — skin (lung meridian)
- • GV-14 — systemic heat
- • DO NOT needle over an active psoriatic plaque
Scientific Evidence
The evidence for PsA is of smaller volume than for AS or RA, but the results point to real benefit, especially in the cutaneous domain when added to conventional treatment.
CLINICAL RESULTS — ACUPUNCTURE IN PSORIATIC ARTHRITIS
| OUTCOME | RESULT | VERSUS | QUALITY |
|---|---|---|---|
| VAS arthralgia (0–10) | −2.8 pts | MTX alone: −1.9 pts | Low-Moderate |
| DAS28 (joint activity) | −0.9 pts | — | Low-Moderate |
| PASI (cutaneous psoriasis) | −4.2 pts (+21% over biologic) | Biologic alone | Low |
| Dactylitis (resolution per digit) | 67% resolution | 40% MTX alone | Low (1 RCT) |
| Quality of life (PsAQoL) | +4.8 pts | — | Low |
Clinical Protocol in Psoriatic Arthritis
Protocol by Dominant Phenotype
Initial Assessment
DAS28, PASI (cutaneous psoriasis), count of dactylitic and enthesitic joints. Biologic or DMARD in use. Photosensitivity (caution with post-session UV in patients with photosensitive psoriasis). Contraindication: do not needle over active plaques — Koebner phenomenon.
Integrated Protocol (Joint + Cutaneous)
Two sessions/week. Fixed protocol: BL-17 + SP-10 (cutaneous), LI-11 + ST-36 (anti-inflammatory), LI-4 + LR-3 (analgesic). Joint protocol: local points in affected joints, Ba Feng for dactylitis. EA at 2 Hz in joints with active synovitis. Enthesitis: peritendinous needling with EA.
Coordination with Dermatologist/Rheumatologist
Monitor PASI and DAS28 monthly. Communicate results to the responsible specialist. Therapy adjustments (phototherapy, biologic, DMARD) are decided by the specialist on an individualized basis — acupuncture complements, it does not replace. No drug interactions described with DMARDs or biologics.
When to Seek Medical Acupuncture in PsA
Priority Indications
- • Mild-to-moderate PsA without yet an indication for biologic
- • Persistent dactylitis despite DMARD
- • Achilles or plantar enthesitis resistant to treatment
- • PsA + moderate cutaneous psoriasis — dual approach
- • Residual arthralgia in patients on biologic
- • Patient who refuses biologic out of fear of immunosuppression
Specific Contraindications
- • Never needle over active psoriatic plaques (Koebner)
- • PsA with acute uveitis: treat the eye first
- • Severe arthritis mutilans: prioritize biologic — acupuncture only as adjuvant
- • Severe immunosuppression (high-dose biologic): hygienic precautions
Frequently Asked Questions
Frequently Asked Questions
No — never insert needles into active psoriasis plaques. The Koebner phenomenon describes the ability of psoriasis to develop at sites of cutaneous trauma — and an acupuncture needle, however small, constitutes trauma. The cutaneous benefit is obtained through needling on healthy skin distant from the plaques (BL-17, SP-10, LI-11, GV-14), which acts through systemic modulation of the IL-17/IL-23 pathway.
No, when performed with correct technique — needling on healthy skin, avoiding active plaques. In clinical studies of psoriasis with hundreds of patients, none reported cutaneous worsening from acupuncture when the protocol of avoiding active plaques was followed. The Koebner phenomenon requires trauma to skin with underlying inflammatory activity — normal healthy skin does not present this risk.
Psoriatic onychodystrophy (pitting, onycholysis, subungual hyperkeratosis) has limited response to acupuncture — and also to non-biologic conventional treatments. Anti-IL-17 and anti-IL-23 biologics are the most effective for nail manifestation. Acupuncture can contribute modestly via BL-17 and SP-10 (systemic cutaneous improvement), but is not the treatment of choice for isolated onychodystrophy.
Yes — there is no contraindication between acupuncture and narrowband UVB phototherapy. They are complementary mechanisms: UVB reduces keratinocyte proliferation and acupuncture modulates the systemic immune response. Ideally, perform acupuncture sessions on days alternating with phototherapy. Wait 24 hours after the UVB session before doing acupuncture in the irradiated áreas (skin may be erythematous).